Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselve...

Full description

Bibliographic Details
Main Authors: Sayin, Volkan I., Singh, Simranjit X., LeBoeuf, Sarah E., Karakousi, Triantafyllia R., Martinez, Britney, Bronson, Roderick T., Prigge, Justin R., Schmidt, Edward E., Thomas, Craig J., Goparaju, Chandra, Davies, Angela, Dolgalev, Igor, Heguy, Adriana, Allaj, Viola, Poirier, John T., Moreira, Andre L., Rudin, Charles M., Pass, Harvey I., Papagiannakopoulos, Thales, Davidson, Shawn M., Bauer, Matthew R., Ellis, Donald Christian, Bhutkar, Arjun, Sanchez-Rivera, Francisco Javier, Subbaraj, Lakshmipriya, Vander Heiden, Matthew G., Jacks, Tyler E., Romero, Rodrigo,Ph. D.Massachusetts Institute of Technology.
Other Authors: Massachusetts Institute of Technology. Department of Biology
Format: Article
Published: Nature Publishing Group 2018
Online Access:http://hdl.handle.net/1721.1/116537
https://orcid.org/0000-0003-1689-0784
https://orcid.org/0000-0002-4233-0775
https://orcid.org/0000-0002-6702-4192
https://orcid.org/0000-0001-5785-8911

Internet

http://hdl.handle.net/1721.1/116537
https://orcid.org/0000-0003-1689-0784
https://orcid.org/0000-0002-4233-0775
https://orcid.org/0000-0002-6702-4192
https://orcid.org/0000-0001-5785-8911

Similar Items